Vir Biotechnology CEO George Scangos said on Wednesday he will retire, ending an itinerant, nearly 40-year-career as one of biotech’s most recognizable executives.
Scangos, 74, will be succeeded in April by Marianne De Backer, a longtime pharma executive who currently heads pharmaceutical strategy at Bayer. She will inherit a company that rose to prominence during the pandemic by developing the antibody drug sotrovimab and is trying to repeat the success with a series of candidates for Covid and other infectious diseases.
In an interview, Scangos, noticeably emotional, said his reasons were simple. He had been a biotech CEO, virtually without interruption, since 1996.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
